The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted therapies in HCC
Published: 21 January 2017
Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, elaborates on what COA and COPA are doing to help practices treat their patients at the point of care
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, elaborates ...
Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, explains how PBMs are impacting in-office dispensing for oncology practices
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, explains ...
Ricky Newton on how COA has helped practices keep their in-office dispensing in network
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, considers the success of COA in helping practices keep their in-office dispensing in network
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, considers ...
Ted Okon, MBA, regarding the key issues faced by community oncologists today
Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today
Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today
Ted Okon, MBA, on what COA is doing to help community oncology practices
Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices
Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices
Ted Okon, MBA, considers what can be done to encourage PBM transparency
Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs
Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs
Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM
Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to an alternative payment model (APM)
Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to ...
Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists
Mark Fendrick, MD, considers the challenges associated with value-based insurance design
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to cancer care
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to ...
Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care
Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the impact on delivery of cancer care
Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the ...
Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, explains how PBMs are impacting in-office dispensing for oncology practices
Ricky Newton on how COA has helped practices keep their in-office dispensing in network
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, considers the success of COA in helping practices keep their in-office dispensing in network
Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care
Ricky Newton, Treasurer and Director of Financial Services and Operations, Head, Community Oncology Pharmacy Association (COPA), Community Oncology Alliance, elaborates on what COA and COPA are doing to help practices treat their patients at the point of care
Ted Okon, MBA, on what COA is doing to help community oncology practices
Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices
Ted Okon, MBA, considers what can be done to encourage PBM transparency
Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs
Ted Okon, MBA, regarding the key issues faced by community oncologists today
Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today
Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves
Dr. Atkins, Practicing Physician, Augusta Oncology Associates, Board of Directors, COA, Member at Large, Executive Committee, COA, Medical Co-Chair, CPAN, regarding what cancer patients can do to advocate for themselves and each other
Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care
Rebecca A. Kirch, JD, Executive Vice President, healthcare Quality & Value, National Patient Advocate Foundation, tells us how CMS and commercial insurers have embraced palliative care
Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves
Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, describes what cancer patients can do to advocate for themselves
Nate Brown explains why a practice should participate in MIPS
Nate Brown, Senior Product Marketing Manager, Flatiron Health, provides opinion on why practices should participate in MIPS and not necessarily OCM
Robert Rifkin, MD, explains the key features of biosimilars
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, elaborates on the key features of biosimilars
Michael Diaz, MD, considers what PBMs can do to help community oncology
Dr. Diaz, Director of Patient Advocacy, Florida Cancer Specialists, VP, Community Oncology Alliance, offers opinion on what PBMs can do to help community oncology practices
Nate Brown regarding the steps a practice should take to get started on MIPS
Nate Brown, Senior Product Marketing Manager, Flatiron Health, discusses how a practice not already participating in MIPS can get started
Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, discusses what the regulatory pathway looks like for gaining FDA approval of a biosimilar
Mark Fendrick, MD, explains the motivation behind value-based insurance design
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, tells us about the motivation behind value-based insurance design
Nate Brown speculates on the future of MIPS and oncology practices
Nate Brown, Senior Product Marketing Manager, Flatiron Health, describes how MIPS might look to oncology practices in the future
Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, considers how extrapolation and interchangeability impact the use of biosimilars for cancer patients
Mark Fendrick, MD, provides examples of value-based insurance design in oncology care
Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, shares examples of value-based insurance design in oncology care
Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM
Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to an alternative payment model (APM)
Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists
Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.